Literature DB >> 20818432

Transgenic expression of human cathepsin B promotes progression and metastasis of polyoma-middle-T-induced breast cancer in mice.

L Sevenich1, F Werner, M Gajda, U Schurigt, C Sieber, S Müller, M Follo, C Peters, T Reinheckel.   

Abstract

Elevated expression of the cysteine protease cathepsin B (CTSB) has been correlated with a poor prognosis for cancer patients. In order to model high CTSB expression in mammary cancer, transgenic mice expressing human CTSB were crossed with transgenic polyoma virus middle T oncogene breast cancer mice (mouse mammary tumor virus-PymT), resulting in a 20-fold increase in cathepsin B activity in the tumors of double-transgenic animals. CTSB expression did not affect tumor onset, but CTSB transgenic mice showed accelerated tumor growth with significant increase in weight for end-stage tumors, as well as an overall worsening in their histopathological grades. Notably, the lung metastases in the CTSB transgenic animals were found to be both significantly larger and to occur at a significantly higher frequency. Ex vivo analysis of primary PymT tumor cells revealed no significant effects from elevated CTSB levels on tumor cell characteristics, that is, the formation of tumor cell colonies and the sprouting of invasive strands from PymT cell spheroids. However, tumors from CTSB-overexpressing mice showed increased numbers of tumor-associated B cells and mast cells. In addition, more CD31+ endothelial cells were detected in these tumors, correlating with higher levels of vascular endothelial growth factor (VEGF) being present in the tumor and serum. We conclude that elevated proteolytic CTSB activity facilitates progression and metastasis of PymT-induced mammary carcinomas, and is associated with increased immune cell infiltration, enhanced VEGF levels and the promotion of tumor angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20818432     DOI: 10.1038/onc.2010.387

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  46 in total

Review 1.  Pathomimetic cancer avatars for live-cell imaging of protease activity.

Authors:  Kyungmin Ji; Joshua Heyza; Dora Cavallo-Medved; Bonnie F Sloane
Journal:  Biochimie       Date:  2015-09-12       Impact factor: 4.079

2.  Cathepsin B inhibition limits bone metastasis in breast cancer.

Authors:  Nimali P Withana; Galia Blum; Mansoureh Sameni; Clare Slaney; Arulselvi Anbalagan; Mary B Olive; Bradley N Bidwell; Laura Edgington; Ling Wang; Kamiar Moin; Bonnie F Sloane; Robin L Anderson; Matthew S Bogyo; Belinda S Parker
Journal:  Cancer Res       Date:  2012-01-19       Impact factor: 12.701

3.  Cathepsin B: Basis Sequence: Mouse.

Authors:  Dora Cavallo-Medved; Kamiar Moin; Bonnie Sloane
Journal:  AFCS Nat Mol Pages       Date:  2011-04-10

4.  Deletion of cysteine cathepsins B or L yields differential impacts on murine skin proteome and degradome.

Authors:  Stefan Tholen; Martin L Biniossek; Martina Gansz; Alejandro Gomez-Auli; Fee Bengsch; Agnes Noel; Jayachandran N Kizhakkedathu; Melanie Boerries; Hauke Busch; Thomas Reinheckel; Oliver Schilling
Journal:  Mol Cell Proteomics       Date:  2012-12-10       Impact factor: 5.911

Review 5.  Cathepsin B: multiple roles in cancer.

Authors:  Neha Aggarwal; Bonnie F Sloane
Journal:  Proteomics Clin Appl       Date:  2014-03-26       Impact factor: 3.494

6.  Inactivation of tristetraprolin in chronic hypoxia provokes the expression of cathepsin B.

Authors:  Dominik C Fuhrmann; Michaela Tausendschön; Ilka Wittig; Mirco Steger; Martina G Ding; Tobias Schmid; Nathalie Dehne; Bernhard Brüne
Journal:  Mol Cell Biol       Date:  2014-12-01       Impact factor: 4.272

7.  Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression.

Authors:  F Bengsch; A Buck; S C Günther; J R Seiz; M Tacke; D Pfeifer; D von Elverfeldt; L Sevenich; L E Hillebrand; U Kern; M Sameni; C Peters; B F Sloane; T Reinheckel
Journal:  Oncogene       Date:  2013-09-30       Impact factor: 9.867

8.  Chemical inhibition of prometastatic lysyl-tRNA synthetase-laminin receptor interaction.

Authors:  Dae Gyu Kim; Jin Young Lee; Nam Hoon Kwon; Pengfei Fang; Qian Zhang; Jing Wang; Nicolas L Young; Min Guo; Hye Young Cho; Ameeq Ul Mushtaq; Young Ho Jeon; Jin Woo Choi; Jung Min Han; Ho Woong Kang; Jae Eun Joo; Youn Hur; Wonyoung Kang; Heekyoung Yang; Do-Hyun Nam; Mi-Sook Lee; Jung Weon Lee; Eun-Sook Kim; Aree Moon; Kibom Kim; Doyeun Kim; Eun Joo Kang; Youngji Moon; Kyung Hee Rhee; Byung Woo Han; Jee Sun Yang; Gyoonhee Han; Won Suk Yang; Cheolju Lee; Ming-Wei Wang; Sunghoon Kim
Journal:  Nat Chem Biol       Date:  2013-11-10       Impact factor: 15.040

9.  Elimination of epithelial-like and mesenchymal-like breast cancer stem cells to inhibit metastasis following nanoparticle-mediated photothermal therapy.

Authors:  Hayley J Paholak; Nicholas O Stevers; Hongwei Chen; Joseph P Burnett; Miao He; Hasan Korkaya; Sean P McDermott; Yadwinder Deol; Shawn G Clouthier; Tahra Luther; Qiao Li; Max S Wicha; Duxin Sun
Journal:  Biomaterials       Date:  2016-06-23       Impact factor: 12.479

Review 10.  Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response.

Authors:  Oakley C Olson; Johanna A Joyce
Journal:  Nat Rev Cancer       Date:  2015-12       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.